Wells Fargo’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-43,702
| Closed | -$2.07M | – | 7103 |
|
|
2025
Q3 | $2.07M | Buy |
43,702
+5,946
| +16% | +$288K | ﹤0.01% | 3269 |
|
|
2025
Q2 | $2.01M | Sell |
37,756
-5,980
| -14% | -$272K | ﹤0.01% | 3210 |
|
|
2025
Q1 | $1.77M | Sell |
43,736
-18,131
| -29% | -$769K | ﹤0.01% | 3259 |
|
|
2024
Q4 | $1.72M | Buy |
61,867
+7,587
| +14% | +$230K | ﹤0.01% | 3311 |
|
|
2024
Q3 | $1.56M | Buy |
54,280
+24,829
| +84% | +$647K | ﹤0.01% | 3234 |
|
|
2024
Q2 | $691K | Buy |
29,451
+9,325
| +46% | +$199K | ﹤0.01% | 3713 |
|
|
2024
Q1 | $508K | Buy |
20,126
+5,763
| +40% | +$138K | ﹤0.01% | 3880 |
|
|
2023
Q4 | $335K | Sell |
14,363
-31,243
| -69% | -$616K | ﹤0.01% | 4138 |
|
|
2023
Q3 | $2.31M | Sell |
45,606
-2,845
| -6% | -$132K | ﹤0.01% | 2694 |
|
|
2023
Q2 | $2.26M | Buy |
48,451
+11,834
| +32% | +$542K | ﹤0.01% | 2802 |
|
|
2023
Q1 | $1.4M | Buy |
36,617
+34,800
| +1,915% | +$1.55M | ﹤0.01% | 3147 |
|
|
2022
Q4 | $99.6K | Buy |
1,817
+82
| +5% | +$3.51K | ﹤0.01% | 4533 |
|
|
2022
Q3 | $59K | Sell |
1,735
-67
| -4% | -$1.02K | ﹤0.01% | 4872 |
|
|
2022
Q2 | $17K | Sell |
1,802
-2,286
| -56% | -$23.8K | ﹤0.01% | 5521 |
|
|
2022
Q1 | $58K | Sell |
4,088
-8,862
| -68% | -$155K | ﹤0.01% | 5576 |
|
|
2021
Q4 | $274K | Buy |
12,950
+12,473
| +2,615% | +$277K | ﹤0.01% | 5084 |
|
|
2021
Q3 | $11K | Buy |
477
+250
| +110% | +$5.66K | ﹤0.01% | 6158 |
|
|
2021
Q2 | $6K | Sell |
227
-150
| -40% | -$4.21K | ﹤0.01% | 6267 |
|
|
2021
Q1 | $11K | Sell |
377
-29,645
| -99% | -$897K | ﹤0.01% | 6304 |
|
|
2020
Q4 | $774K | Buy |
30,022
+23,629
| +370% | +$657K | ﹤0.01% | 4209 |
|
|
2020
Q3 | $196K | Sell |
6,393
-14,941
| -70% | -$522K | ﹤0.01% | 4973 |
|
|
2020
Q2 | $532K | Buy |
21,334
+15,189
| +247% | +$347K | ﹤0.01% | 4284 |
|
|
2020
Q1 | $130K | Buy |
6,145
+2,981
| +94% | +$63.9K | ﹤0.01% | 4927 |
|
|
2019
Q4 | $70K | Buy |
3,164
+2,778
| +720% | +$57.5K | ﹤0.01% | 5413 |
|
|
2019
Q3 | $9K | Buy |
+386
| New | +$8.98K | ﹤0.01% | 5949 |
|
Other funds holding AKRO
Wells Fargo's AKRO Position: Q4 2025 in Review
Wells Fargo sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 43,702 shares — an estimated $2.07M sold.
Wells Fargo first reported a position in AKRO in Q3 2019 and held it in 25 quarters. The position peaked at $2.31M in Q3 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Wells Fargo reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Wells Fargo sold 43,702 Akero Therapeutics shares in Q4 2025, an estimated $2.07M.
- Wells Fargo first reported a position in Akero Therapeutics in Q3 2019 and held it in 25 quarters.
- Wells Fargo's Akero Therapeutics position peaked at $2.31M in Q3 2023.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Wells Fargo's 13F filing for Q4 2025, filed 13 Feb 2026.